Lichen planus is a chronic inflammatory skin condition that affects the skin and mucous membranes. It is characterized by itchy, scaly purple-colored rashes or lesions on the wrists, legs, and back. Biologics drugs are monoclonal antibodies which are specifically engineered to target and inhibit certain molecules responsible for inflammatory diseases. The growing licensing of biologics drugs over the past few years are aiding the treatment of lichen planus. Topical corticosteroids, antihistamines, and immunosuppressant drugs have traditionally been used for symptomatic relief and disease control. However, biologics are increasingly gaining popularity owing to their higher efficacy and reduced side effects.

The Global Lichen Planus Market is estimated to be valued at USD 150.1 million in 2024 and is expected to reach USD 251.2 million by 2031, growing at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031.


Key Takeaways

Key players operating in the lichen planus market are Astellas Pharma Inc., Bristol-Myers Squibb, CELGENE CORPORATION, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc.

The availability of advanced treatment options such as targeted therapies and biologics drugs are creating new opportunities in the market.

Technological advancements in drug delivery systems have enabled development of effective topical and injectable treatments for Lichen Planus Market. Advancements in biologics revolutionized the treatment landscape.



Market Drivers

Rising geriatric population who are more prone to develop lichen planus is a major driver for market growth. According to the United Nations, the global population aged 60 years and above is projected to grow from 962 million in 2017 to 2.1 billion in 2050. Growing awareness about available treatment options is also fueling the demand.

Current challenges in Lichen Planus market

Lichen planus is a chronic inflammatory disease that commonly affects the skin, oral cavity, genitalia, scalp, and nails. Diagnosis of this condition can be challenging due to its appearance mimicking other diseases. Further, the exact cause of lichen planus is still unknown which makes it difficult to develop targeted treatment options. Symptoms may come and go which causes psychological stress to patients. Existing topical corticosteroids provide temporary relief and their long term usage can cause side-effects.



SWOT Analysis

Strength: Growing awareness about lichen planus leads to early diagnosis. Developing non-invasive diagnostic tools ease identification.

Weakness: Etiology still unclear hampers drug development. Topical medications have short term effects and side effects on prolonged use.

Opportunity: Scope for new oral agents, phototherapy and immunotherapy. Potential for combination therapies targeting specific pathways.

Threats: High recurrence rate poses treatment challenges. Limited understanding impacts management.



Geographical regions

North America currently dominates the lichen planus market in terms of value led by developed healthcare infrastructure and awareness levels in the US and Canada.



Fastest growing region

Asia Pacific is poised to be the fastest growing regional market during the forecast period attributed to improving access to diagnosis and treatment options especially in India and China coupled with rising incidence of lichen planus.

Get this Report in Japanese Language: 扁平紅色苔癬市場

Get this Report in Korean Language: 편평태선 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)